NCT04716231Phase 3Active not recruiting

Atacicept in Subjects With IgA Nephropathy

Study sponsor: Vera Therapeutics, Inc. · VERA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-05-15Actual
Enrollment · participants428Actual
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in urine protein to creatinine ratio (UPCR) Description: UPCR based on 24 hour urine collection Time frame: 36 Weeks. After: Measure: Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) Description: Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period. Time frame: 36 Weeks.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 376 participants (planned). After: 428 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview